Skip to main content

PSMA Targeted Imaging and Therapy: Prostate and Other Cancers

  1. Brain metastases from prostate cancer are rare and usually only occur in the context of widespread systemic disease. This is the first case report of a solitary brain oligometastasis, in a neurologically intac...

    Authors: M. I. Ross, N. Bird, I. A. Mendichovszky and Y. L. Rimmer

    Citation: EJNMMI Research 2020 10:108

    Content type: Case report

    Published on:

  2. Focal therapies or focally escalated therapies of primary prostate cancer are becoming more and more important. This increases the need to identify the exact extension of the intraprostatic tumor and possible ...

    Authors: Thomas Franz Fassbender, Florian Schiller, Constantinos Zamboglou, Vanessa Drendel, Selina Kiefer, Cordula A. Jilg, Anca-Ligia Grosu and Michael Mix

    Citation: EJNMMI Research 2020 10:62

    Content type: Original research

    Published on:

  3. To investigate the added value and diagnostic accuracy of 68Ga-PSMA PET/CT versus bone scintigraphy (BS) for bone metastasis detection at the primary staging of prostate cancer (PCa).

    Authors: Helle D. Zacho, Søren Ravn, Ali Afshar-Oromieh, Joan Fledelius, June A. Ejlersen and Lars J. Petersen

    Citation: EJNMMI Research 2020 10:31

    Content type: Original research

    Published on:

  4. Differentiated thyroid carcinoma (DTC) is the most common type of thyroid cancer. Treatment with surgery, radioactive iodine (RAI), and TSH suppression is effective in most patients. Five to 15% of patients be...

    Authors: Lisa H. de Vries, Lutske Lodewijk, Arthur J. A. T. Braat, Gerard C. Krijger, Gerlof D. Valk, Marnix G. E. H. Lam, Inne H. M. Borel Rinkes, Menno R. Vriens and Bart de Keizer

    Citation: EJNMMI Research 2020 10:18

    Content type: Preliminary research

    Published on:

  5. Identification of suspicious PSMA-PET/CT-positive lymph node (LN) metastases (LNM) from prostate cancer (PCa) during lymphadenectomy (LA) is challenging. We evaluated an 111In-labelled PSMA ligand (DKFZ-617, refe...

    Authors: Cordula A. Jilg, Kathrin Reichel, Christian Stoykow, H. Christian Rischke, Mark Bartholomä, Vanessa Drendel, Moritz von Büren, Wolfgang Schultze-Seemann, Philipp T. Meyer and Michael Mix

    Citation: EJNMMI Research 2020 10:17

    Content type: Original research

    Published on:

  6. Prostate-specific membrane antigen (PSMA) ligand PET/CT has already provided promising results in prostate cancer (PC) imaging, yet simple and reproductible reporting criteria are still lacking. This study aim...

    Authors: Céline Derwael, Olivier Lavergne, Pierre Lovinfosse, Vlad Nechifor, Mallory Salvé, David Waltregny, Roland Hustinx and Nadia Withofs

    Citation: EJNMMI Research 2020 10:15

    Content type: Original research

    Published on:

  7. Several scan parameters for PET imaging with 18F-PSMA-11 such as dosage, acquisition time and scan duration were evaluated to determine the most appropriate scan protocol, as well as the effect of furosemide admi...

    Authors: Sarah Piron, Kathia De Man, Vanessa Schelfhout, Nick Van Laeken, Ken Kersemans, Eric Achten, Filip De Vos and Piet Ost

    Citation: EJNMMI Research 2020 10:14

    Content type: Original research

    Published on:

  8. The positron emission tomography (PET) ligand 68Ga-Glu-urea-Lys(Ahx)-HBED-CC (68Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although 68Ga-PSMA-11 PET i...

    Authors: Anna Ringheim, Guilherme de Carvalho Campos Neto, Udunna Anazodo, Lumeng Cui, Marcelo Livorsi da Cunha, Taise Vitor, Karine Minaif Martins, Ana Cláudia Camargo Miranda, Marycel Figols de Barboza, Leonardo Lima Fuscaldi, Gustavo Caserta Lemos, José Roberto Colombo Junior and Ronaldo Hueb Baroni

    Citation: EJNMMI Research 2020 10:12

    Content type: Original research

    Published on: